T1	Participants 64 116	peripheral blood of patients with malignant neoplasm
T2	Participants 207 239	patients with malignant neoplasm
T3	Participants 544 555	51 patients
T4	Participants 275 286	51 patients
T5	Participants 997 1017	patients with cancer
